Correction to: Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort

Nseir, Saad; Martín‐Loeches, Ignacio; Póvoa, Pedro; Metzelard, Matthieu; Cheyron, Damien du; Lambiotte, Fabien; Tamion, Fabienne; Labruyère, Marie; Makris, Demosthènes; Geronimi, Claire Boulle; Chambrun, Marc Pinetonde; Nyunga, Martine; Pouly, Olivier; Mégarbane, Bruno; Saade, Anastasia; Gomà, Gemma; Magira, Eleni; Llitjos, Jean-François; Torres, Antoni; Ioannidou, Iliana; Pierre, Alexandre; Coelho, Luís; Reignier, Jean; Garot, Denis; Kreitmann, Louis; Baudel, Jean-Luc; Voiriot, Guillaume; Contou, Damien; Beurton, Alexandra; Asfar, Pierre; Boyer, Alexandre; Thille, Arnaud W.; Mekontso-Dessap, Armand; Tsolaki, Vasiliki; Vinsonneau, Christophe; Floch, Pierre-Edouard; Guennec, Loïc Le; Ceccato, Adrián; Artigas, Antonio; Bouchereau, Mathilde; Labreuche, Julien; Duhamel, Alain; Rouzé, Anahita; Favory, Raphaël; Preau, Sébastien; Jourdain, M.; Poissy, Julien; Leger, Piehr Saint; Linden, Thierry Van Der; Veinstein, Anne; Azoulay, Élie; Pène, Frédéric; Martin, Maëlle; Razazi, Keyvan; Plantefève, Gaëtan; Fartoukh, Muriel; Thévenin, Didier; Guidet, Bertrand; Weiss, Nicolas; Kouatchet, Achille; Salmon, Charlotte; Brunin, Guillaume; Nemlaghi, Safaa; Meguerditchian, David; Argaud, Laurent; Voicu, Sébastian; Luyt, Charles‐Édouard; Kowalski, Benjamin; Moglia, Edgar; Morales, Luis; Koutsoukou, Antonia; Mentzelopoulos, Spyros D.; Nora, David; Boyd, Sean; Maizel, Julien; Cuchet, Pierre; Delforge, Quentin; Quenot, Jean-Pierre; Boyer, Déborah; Cillóniz, Catia

doi:10.1186/s13054-021-03713-3

Cited by 3 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found no between-group difference in VAP incidence after considering extubation and death within 90 days as competing events. In our study, VAP was not associated with higher 90-day mortality, in contrast with previous studies (30). Previous studies did not report an increased risk of ICU-acquired infection associated with HDCT use in patients having nonresolving ARDS (11,12).…”

Section: Discussioncontrasting

confidence: 99%

High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*

Lopinto

Arrestier

Peiffer

et al. 2023

Critical Care Medicine

View full text Add to dashboard Cite

OBJECTIVES: To determine the impact of high doses of corticosteroids (HDCT) in critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) who had been previously treated with dexamethasone as a standard of care. DESIGN: Prospective observational cohort study. Eligible patients presented nonresolving ARDS related to severe acute respiratory syndrome coronavirus 2 infection and had received initial treatment with dexamethasone. We compared patients who had received or not HDCT during ICU stay, consisting of greater than or equal to 1 mg/kg of methylprednisolone or equivalent for treatment of nonresolving ARDS. The primary outcome was 90-day mortality. We assessed the impact of HDCT on 90-day mortality using univariable and multivariable Cox regression analysis. Further adjustment for confounding variables was performed using overlap weighting propensity score. The association between HDCT and the risk of ventilator-associated pneumonia was estimated using multivariable cause-specific Cox proportional hazard model adjusting for pre-specified confounders. SETTING: We included consecutive patients admitted in 11 ICUs of Great Paris area from September 2020 to February 2021. PATIENTS: Three hundred eighty-three patients were included (59 in the HDCT group, 324 in the no HDCT group). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: At day 90, 30 of 59 patients (51%) in the HDCT group and 116 of 324 patients (35.8%) in the no HDCT group had died. HDCT was significantly associated with 90-day mortality in unadjusted (hazard ratio [HR], 1.60; 95% CI, 1.04–2.47; p = 0.033) and adjusted analysis with overlap weighting (adjusted HR, 1.65; 95% CI, 1.03–2.63; p = 0.036). HDCT was not associated with an increased risk of ventilator-associated pneumonia (adjusted cause-specific HR, 0.42; 95% CI, 0.15–1.16; p = 0.09). CONCLUSIONS: In critically ill COVID-19 patients with nonresolving ARDS, HDCT result in a higher 90-day mortality.

show abstract

Section: Discussioncontrasting

confidence: 99%

High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*

Lopinto

Arrestier

Peiffer

et al. 2023

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…About that, Italy is one of the six countries reporting a CFR of > 10%, and approximately 23% of people aged 65 years old or older may explain this higher CFR [ 16 ]. Several influencing factors can also be found on differences in time lags between reporting of infections and deaths: some may be detected on healthcare system organization as infrastructures and surveillance capacities others to patients’ general conditions as aged comorbidity [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Should we operate on all patients with COVID-19 and proximal femoral fractures? An analysis of thirty, sixty, and ninety day mortality rates based on patients’ clinical presentation and comorbidity: a multicentric study in Northern Italy

Fusini¹,

Massè

Risitano

et al. 2021

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose This study aims to evaluate 30–60–90-day mortality of operated proximal femur fractures (PFFs) suffering from COVID-19 and correlation with patients’ clinical presentation and comorbidities. Methods Between February 1, 2020, and December 31, 2020, patients with COVID-19 infection and surgically treated PFF were included. Patients’ demographic characteristics, oxygen (O2) therapy, comorbidities, and AO type fracture were collected. Chi-square test or Fisher test and hazard ratio were used to assessing the correlation between mortality rate, patient characteristics, and COVID-19 status. Kaplan-Meyer curve was used to analyze 30–60–90-day mortality. Level of significance was set as p < 0.05. Results Fifty-six patients (mean age of 82.7 ± 8.85 years) were included. Thirty-day mortality rate was 5%, which increased to 21% at 60 days and 90 days. Eleven patients died, eight due to AO type A-like and three due to AO type B-like fractures. No significant difference in mortality rate between patients with cardiopulmonary comorbidity or no cardiopulmonary comorbidity was found ( p = 0.67); a significant difference in patients with chronic obstructive pulmonary disease (COPD) or history of pulmonary embolism (PE) and patients without COPD was found ( p = 0.0021). A significant difference between asymptomatic/mild symptomatic COVID-19 status and symptomatic COVID-19 status was found ( p = 0.0415); a significant difference was found for O2 therapy with < 4 L/min and O2 therapy ≥ 4 L/min ( p = 0.0049). Conclusion Thirty-day mortality rate of COVID-19 infection and PFFs does not differ from mortality rate of non-COVID-19 PFFs. However, patients with pre-existing comorbidities and symptomatic COVID-19 infection requiring a high volume of O2 therapy have a higher incidence of 60–90-day mortality when surgically treated.

show abstract

“…The COVID-19 pandemic has accumulated a high number of deaths 1 , where it has been estimated that approximately 80% of patients admitted to intensive care units (ICU) require mechanical ventilation, which is a risk factor for the development of ventilator-associated pneumonia (VAP) 2 , 3 . Patient-associated comorbidities are another risk factor that increases the likelihood of acquiring VAP, complicating the clinical condition of COVID-19 patients and directly impacting the mortality 2 , 4 , 5 , 6 . Among the causative agents of VAP in COVID-19 patients are those belonging to the ESKAPE group 7 , 8 , 9 .…”

Section: Introductionmentioning

confidence: 99%

“…This acronym is composed of bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., among others 10 , 11 . These bacteria have been recognised as pathogens in critically ill and immunocompromised individuals, and may be associated with resistance to multiple antibiotics 5 , 12 , 13 . The hospital environment play an important role in the development of Healthcare-Associated Infections (HAI) including VAP 14 , 15 .…”

Section: Introductionmentioning

confidence: 99%

ESKAPE bacteria characterization reveals the presence of Acinetobacter baumannii and Pseudomonas aeruginosa outbreaks in COVID-19/VAP patients

Loyola-Cruz

Durán-Manuel

Cruz-Cruz

et al. 2023

American Journal of Infection Control

View full text Add to dashboard Cite

Correction to: Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort

Cited by 3 publications

References 1 publication

High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*

High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*

Should we operate on all patients with COVID-19 and proximal femoral fractures? An analysis of thirty, sixty, and ninety day mortality rates based on patients’ clinical presentation and comorbidity: a multicentric study in Northern Italy

ESKAPE bacteria characterization reveals the presence of Acinetobacter baumannii and Pseudomonas aeruginosa outbreaks in COVID-19/VAP patients

Contact Info

Product

Resources

About